Immunoprecise Antibodies Ltd - Asset Resilience Ratio
Immunoprecise Antibodies Ltd (IPA) has an Asset Resilience Ratio of 3.43% as of January 2017. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1997–2020)
This chart shows how Immunoprecise Antibodies Ltd's Asset Resilience Ratio has changed over time. Check IPA strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Immunoprecise Antibodies Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see IPA market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $156.92K | 3.43% |
| Total Liquid Assets | $156.92K | 3.43% |
Asset Resilience Insights
- Limited Liquidity: Immunoprecise Antibodies Ltd maintains only 3.43% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Immunoprecise Antibodies Ltd Industry Peers by Asset Resilience Ratio
Compare Immunoprecise Antibodies Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Immunoprecise Antibodies Ltd (1997–2020)
The table below shows the annual Asset Resilience Ratio data for Immunoprecise Antibodies Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2020-04-30 | 0.00% | $104.00 | $27.26 Million | -- |
| 2017-04-30 | 0.00% | $0.00 | $3.93 Million | -- |
| 2016-04-30 | 15.51% | $214.14K | $1.38 Million | +15.04pp |
| 2010-04-30 | 0.47% | $26.00K | $5.53 Million | +0.00pp |
| 2009-04-30 | 0.47% | $32.50K | $6.93 Million | -4.44pp |
| 2008-04-30 | 4.91% | $253.25K | $5.16 Million | +4.37pp |
| 2007-04-30 | 0.54% | $31.34K | $5.84 Million | +0.31pp |
| 2006-04-30 | 0.22% | $9.00K | $4.05 Million | -0.59pp |
| 2001-04-30 | 0.81% | $9.40K | $1.16 Million | +0.24pp |
| 1999-04-30 | 0.57% | $9.40K | $1.66 Million | -6.17pp |
| 1998-04-30 | 6.73% | $197.32K | $2.93 Million | -50.56pp |
| 1997-04-30 | 57.30% | $2.22 Million | $3.88 Million | -- |
About Immunoprecise Antibodies Ltd
ImmunoPrecise Antibodies Ltd. operates as an AI-driven biotherapeutic research, technology, and scientifically robust life science company. It discovers and develops customized and novel antibodies by generating proprietary and patented processes, procedures, and innovative approaches to antibody discovery, development, and production. The company was incorporated in 1983 and is headquartered in … Read more